MedTrace Logo

Non Transplantable Recurrence After Percutaneous Thermal Ablation of HCC

NCT05202184 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 213

Last updated 2022-02-08

No results posted yet for this study

Summary

Percutaneous thermal ablation (PTA), resection and liver transplantation (LT) are the standard curative options for hepatocellular carcinoma (HCC). LT yields the best long-term outcomes but is limited by graft shortage. Thus, patients with ≤3cm HCC are mainly treated by PTA although recurrence is frequent and may occur outside transplant criteria. However, data on non transplantable recurrence (NTR) following PTA are lacking. Therefore, the investigators investigated the incidence and predictors of NTR among transplantable patients with ≤3cm HCC(s) treated by PTA, in order to stratify them according to their NTR risk and to improve treatment allocation.

Conditions

Interventions

PROCEDURE

Percutaneous thermal ablation

All thermoablation procedures were performed percutaneously under ultrasound and/or CT guidance

Sponsors & Collaborators

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • BORIS GUIU, PU-PH · University Hospital, Montpellier

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2020-12-01
Completion
2020-12-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05202184 on ClinicalTrials.gov